Ajooni Biotech share news, announcements and annual reports
NSE: AJOONIFood ProductsSmall Cap
Ajooni Biotech Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 2018 · Issue price ₹40
Last close ₹2.87down ₹0.06 (2.05%)
Share price at the NSE close on 30 Oct 2026. Previous close ₹2.93.
30 Oct: open ₹2.90, high ₹2.95, low ₹2.86
52-week range of traded prices to 30 Oct 2026
₹2.68Low, 12 Oct 2026₹5.50High, 9 Feb 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹52 Cr3,140th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 13.14
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 4.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 4.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.19
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,11,79585.8% delivered
Ajooni Biotech share news and announcements
531 announcements, routine notices left out, newest first. Page 6 of 11.
Jan 2023
Dec 2022
24 Dec · Committee Meeting Updates
14 Dec · Outcome of committee meeting
13 Dec · Legal
12 Dec · Legal
Exchange has sought clarification from Ajooni Biotech Limited with respect to Financial Results dated 11-Nov-2022 for the period Sep, 2022On the basis of aforesaid disclosure, the Listed entity is required to clarify the following:Standalone: Cash Flow- Not submitted.The response of the company is awaited7 Dec · Legal
Exchange has sought clarification from Ajooni Biotech Limited with respect to announcement dated 29-Nov-2022 informing about Communication to shareholders as per Reg 30.On the basis of aforesaid announcement, the Company is required to provide/clarify the following: 1. Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief). 2. Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"; 3. Name of the target entity, details in brief such as size, turnover etc; 4. Industry to which the entity being acquired belongs; 5. Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity); 6. Brief details of any governmental or regulatory approvals required for the acquisition; 7. Indicative time period for completion of the acquisition; 8. Cost of acquisition or the price at which the shares are acquired; 9. Nature of consideration - whether cash consideration or share swap and details of the same; The response of the company is awaited.
Nov 2022
30 Nov · General updates
29 Nov · Communication to shareholders as per Reg 30
25 Nov · Outcome of committee meeting
21 Nov · Corporate action
21 Nov · Outcome of committee meeting
21 Nov · General updates
18 Nov · Related Party Transaction
11 Nov · General updates
Oct 2022
27 Oct · Outcome of committee meeting
17 Oct · Board meeting
8 Oct · Board meeting
Sep 2022
22 Sep · Corporate action
21 Sep · General updates
21 Sep · Amendment to AOA/MOA
21 Sep · Management
21 Sep · Management
21 Sep · Management
21 Sep · Split of shares
20 Sep · Meeting
7 Sep · General updates
Aug 2022
29 Aug · Legal
Exchange has sought clarification from Ajooni Biotech Limited with respect to announcement dated 25-Aug-2022 informing about the Outcome of Board Meeting.On the basis of aforesaid announcement, the Company is required to provide/clarify the following: 1. Rationale behind the split/consolidation; 2. Pre and post share capital - authorized, paid-up and subscribed; 3. Expected time of completion; 4. Class of shares which are consolidated or subdivided; 5. Number of shares of each class pre and post split or consolidation; 6. Amendments to Memorandum and/or Articles of association of listed entity, in brief. The response of the company is awaited.29 Aug · General updates
27 Aug · General updates
27 Aug · Meeting
18 Aug · General updates
Jul 2022
11 Jul · General updates
Jun 2022
8 Jun · General updates
May 2022
27 May · Related Party Transaction